# EXACERBATIONS AND REAL-WORLD OUTOMES AMONG PATIENTS WITH COPD INITIATING BREZTRI (EROS+CP Japan Study)

> **NCT07103642** · — · COMPLETED · sponsor: **AstraZeneca** · enrollment: 3402 (actual)

## Conditions studied

- Pulmonary Disease, Chronic Obstructive

## Interventions

- **DRUG:** BGF

## Key facts

- **NCT ID:** NCT07103642
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2024-08-15
- **Primary completion:** 2024-10-18
- **Final completion:** 2024-10-18
- **Target enrollment:** 3402 (ACTUAL)
- **Last updated:** 2025-08-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07103642

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07103642, "EXACERBATIONS AND REAL-WORLD OUTOMES AMONG PATIENTS WITH COPD INITIATING BREZTRI (EROS+CP Japan Study)". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT07103642. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*